Aslan Pharmaceuticals Ltd Adr (ASLN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ASLAN Pharmaceuticals has reported promising interim data from its TREK-DX study, with its drug eblasakimab showing significant efficacy in atopic dermatitis patients who had previously not responded to dupilumab. The company is also progressing on two Phase 2 studies, with top-line data expected in the second half of 2024. Financially, ASLAN has seen a decrease in net loss and operating expenses compared to the previous year, alongside a successful registered direct offering.
For further insights into ASLN stock, check out TipRanks’ Stock Analysis page.